Mural Oncology - Crunchbase Company Profile & Funding

Q: Who invested in Mural Oncology?

Mural Oncology is funded by Alkermes.

Q: When was the last funding round for Mural Oncology?

Mural Oncology closed its last funding round on obfuscated from a Corporate Round round.

Q: How much funding has Mural Oncology raised to date?

Mural Oncology has raised obfuscated.

Overview

Mural Oncology

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Mural Oncology

CB Rank

45480

Mural Oncology is a protein engineering platform to reimagine cytokine-based immunotherapies for the treatment of cancer.

Acquired by

XRA 5 Corp

Founded

obfuscation

Public

Corporate Round

Waltham, Massachusetts, United States

101-250

www.muraloncology.com

Health Care

Oncology

Public Relations

Therapeutics

Funding Rounds

Corporate Round

OBF

obfuscation

Key People

Caroline Loew: Founder and Chief Executive Officer

Details

Legal Name

Mural Oncology Plc

Operating Status

Active

Stock Symbol

NASDAQ:MURA

Company Type

For Profit

Founders

Caroline Loew

About the Company

Mural Oncology is an independent public company. Mural Oncology would focus on the discovery and development of cancer therapies, including the continued development of nemvaleukin alfa and the company's portfolio of novel, preclinical engineered cytokines, comprised of tumor-targeted split interleukin-12 (IL-12) and interleukin-18 (IL-18).

Predictions & Insights

Growth Insight

See this Growth Insight

Mural Oncology is

Lorem

to be growing

Top Contributing Factors

Financial Decline

Products & Services

nemvaleukin alfa

A modified interleukin-2 cytokine engineered for cancer immunotherapy, used alone or with pembrolizumab to treat advanced solid tumors.

MURA-7012 (Tumor-Targeted Split IL-12)

A preclinical cytokine therapy that delivers split IL-12 subunits fused to antibodies to concentrate IL-12 activity at tumor sites, reducing systemic toxicity.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Corporate Round - Mural Oncology	1	obfuscated obfuscation	Alkermes	Corporate Round
obfuscated obfuscation	Corporate Round - Mural Oncology	1	obfuscated obfuscation	Alkermes	Corporate Round
obfuscated obfuscation	Corporate Round - Mural Oncology	1	obfuscated obfuscation	Alkermes	Corporate Round
obfuscated obfuscation	Corporate Round - Mural Oncology	1	obfuscated obfuscation	Alkermes	Corporate Round
obfuscated obfuscation	Corporate Round - Mural Oncology	1	obfuscated obfuscation	Alkermes	Corporate Round

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Corporate Round - Mural Oncology	1	obfuscated obfuscation	Alkermes	Corporate Round
obfuscated obfuscation	Corporate Round - Mural Oncology	1	obfuscated obfuscation	Alkermes	Corporate Round
obfuscated obfuscation	Corporate Round - Mural Oncology	1	obfuscated obfuscation	Alkermes	Corporate Round
obfuscated obfuscation	Corporate Round - Mural Oncology	1	obfuscated obfuscation	Alkermes	Corporate Round
obfuscated obfuscation	Corporate Round - Mural Oncology	1	obfuscated obfuscation	Alkermes	Corporate Round

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Alkermes	Yes	Corporate Round - Mural Oncology	—
Alkermes	Yes	Corporate Round - Mural Oncology	—
Alkermes	Yes	Corporate Round - Mural Oncology	—
Alkermes	Yes	Corporate Round - Mural Oncology	—
Alkermes	Yes	Corporate Round - Mural Oncology	—